{"commentary":{"count":236,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":90,"x_thread":85,"podcast":55,"x_video":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04622319\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04622319","nct_id":"NCT04622319","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04622319. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.","label":"Trastuzumab deruxtecan (T-DXd)","type":"EXPERIMENTAL"},{"description":"Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.","label":"Trastuzumab ematansine (T-DM1)","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","NSABP Foundation Inc","GBG Forschungs GmbH","Spanish Breast Cancer Research Group"],"completion_date":{"date":"2028-06-20","type":"ESTIMATED"},"conditions":["HER2-Positive Primary Breast Cancer","Residual Invasive Breast Cancer"],"enrollment":{"count":1600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"DS-8201a","type":"DRUG"},{"name":"T-DM1","type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment","timeFrame":"Randomization to date of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first), up to approximately 57 months postdose"}],"references":[{"citation":"Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramirez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr; DESTINY-Breast05 Trial Investigators. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661. Epub 2025 Dec 10.","pmid":"41370739","type":"DERIVED"},{"citation":"Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093.","pmid":"40073831","type":"DERIVED"}],"start_date":{"date":"2020-12-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","url":"https://clinicaltrials.gov/study/NCT04622319"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04622319"}